What is the difference between Cagrilintide and Petrelintide?

Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Petrelintide is classified as: Long-acting amylin (islet amyloid polypeptide) receptor agonist for weight management. Cagrilintide is investigational and is not an approved medicine. Petrelintide is investigational and is not an approved medicine.

Is Cagrilintide or Petrelintide approved?

Cagrilintide is investigational and is not an approved medicine. Petrelintide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Cagrilintide and Petrelintide?

Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 8 for Petrelintide (evidence grade B).

Compound comparison

Cagrilintide vs Petrelintide

This page sets Cagrilintide and Petrelintide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Cagrilintide
Long-acting amylin (and calcitonin) receptor agonist / amylin analogue
Petrelintide
Long-acting amylin (islet amyloid polypeptide) receptor agonist for weight management
Mechanism: Cagrilintide
In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.
Petrelintide
In plain terms, petrelintide imitates amylin, a hormone released alongside insulin that signals fullness and slows stomach emptying, which reduces how much a person eats.
United States (FDA): Cagrilintide
Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.
Petrelintide
Not approved. Investigational and in clinical development for chronic weight management.
European Union (EMA): Cagrilintide
Not authorized; investigational, no marketing authorization.
Petrelintide
Not authorised. Investigational only.
Australia (TGA): Cagrilintide
Not entered on the ARTG; investigational only and not approved for supply.
Petrelintide
Not registered on the ARTG. Investigational only.
WADA: Cagrilintide
Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.
Petrelintide
Not listed as a prohibited substance on the WADA Prohibited List (2026). Amylin analogs are not classified as prohibited in or out of competition.
Evidence grade: Cagrilintide
B
Petrelintide
B
Tracked clinical trials: Cagrilintide
42
Petrelintide
8
Full profile: Cagrilintide
Cagrilintide profile
Petrelintide
Petrelintide profile

Comparison of Cagrilintide and Petrelintide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Cagrilintide	Petrelintide
Class	Long-acting amylin (and calcitonin) receptor agonist / amylin analogue	Long-acting amylin (islet amyloid polypeptide) receptor agonist for weight management
Mechanism	In plain terms, cagrilintide mimics amylin, a hormone released with insulin that promotes fullness and slows digestion.	In plain terms, petrelintide imitates amylin, a hormone released alongside insulin that signals fullness and slows stomach emptying, which reduces how much a person eats.
United States (FDA)	Investigational; not approved as a standalone product. As part of the CagriSema combination (with semaglutide), a new drug application has been filed and an FDA decision is expected later in 2026.	Not approved. Investigational and in clinical development for chronic weight management.
European Union (EMA)	Not authorized; investigational, no marketing authorization.	Not authorised. Investigational only.
Australia (TGA)	Not entered on the ARTG; investigational only and not approved for supply.	Not registered on the ARTG. Investigational only.
WADA	Not listed on the WADA Prohibited List. Amylin analogues are not banned substances; as an investigational agent it falls outside approved therapeutic use.	Not listed as a prohibited substance on the WADA Prohibited List (2026). Amylin analogs are not classified as prohibited in or out of competition.
Evidence grade	B	B
Tracked clinical trials	42	8
Full profile	Cagrilintide profile	Petrelintide profile

Common questions

What is the difference between Cagrilintide and Petrelintide?: Cagrilintide is classified as: Long-acting amylin (and calcitonin) receptor agonist / amylin analogue. Petrelintide is classified as: Long-acting amylin (islet amyloid polypeptide) receptor agonist for weight management. Cagrilintide is investigational and is not an approved medicine. Petrelintide is investigational and is not an approved medicine.
Is Cagrilintide or Petrelintide approved?: Cagrilintide is investigational and is not an approved medicine. Petrelintide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Cagrilintide and Petrelintide?: Peptide Science Daily tracks 42 registered clinical trials for Cagrilintide (evidence grade B) and 8 for Petrelintide (evidence grade B).